Showing items 1 - 6 of 6

Your selections:

BRAF and NRAS mutational status are prognostically important in thick and locally advanced cutaneous melanoma

- Vilain, R., Braye, S. G., Ashman, L., Scott, R. J.

CAVATAK (Coxsackievirus A21) displays potent oncolytic activity in BRAFV600E mutant melanoma cells resistant to selective BRAF kinase inhibitors

- Shafren, D. R., Farrelly, M., Croft, A. J., Davies, B., Stewart, J., Ingham, R., Quah, M. Y., Au, G., Hersey, P.

Developing chemotherapeutics which disable the actin cytoskeleton of melanoma cells

- Stehn, J. R., Haass, N. K., Hardeman, E., Winlaw, D., Weninger, W., Gunning, P., Desouza, M., Sequeira, V. B., Treutlein, H., Zeng, J., Nascimento, P. R. B. B., Butler, T., McCluskey, Adam, Palmer, S.

Downstream effects of reduction in nucleotide excision repair in response to cisplatin treatment in melanoma

- Bowden, N. A., Ashton, K. A., Avery-Kiejda, K. A., Zhang, X. D., Hersey, P., Scott, R. J.

Phosphatidylinositol 4,5-Bisphosphate 5-Phosphatase A regulates PI3K/Akt signaling in human melanoma cells

- Ye, Y., Jin, L., Zhang, L. J., Scolyer, R., Hersey, P., Zhang, X. D., Wilmott, J., Hu, W. L., Thorne, R. F., Dong, L., de Bock, C., Jiang, C. C., Rizos, H., Wu, M.

Targeting anti-apoptotic mechanisms for reversal of resistance to BRAF inhibitors in melanoma

- Hersey, P., Wroblewski, D., Lai, F., Jiang, C. C., Zhang, X. D.

  • 1
  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit